Trials on ICS-283 will begin in 2008.



Intradigm chose Agilent Technologies to manufacture the active siRNA component of its RNAi therapeutic. In addition, Intradigm selected ICS-283 as its lead RNAi product candidate.


Under terms of the agreement, Agilent will support the initiation of clinical development for ICS-283. Intradigm expects to initiate trials in 2008.


ICS-283 is the only systemic RNAi therapeutic in preclinical development against a clinically validated oncology target (vascular endothelial growth factor or VEGF), according to Intradigm. It is a nanoparticle-based compound comprised of multiple siRNAs that target both VEGF and its receptor.








This site uses Akismet to reduce spam. Learn how your comment data is processed.